TESARO, Inc. (TSRO)
(Delayed Data from NSDQ)
$74.96 USD
0.00 (0.00%)
Updated Jan 18, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TSRO]
Reports for Purchase
Showing records 1 - 20 ( 141 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
We are dropping coverage of Tesaro due to completion of its acquisition by GlaxoSmithKline Not Covered.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
TESARO Proposed Acquisition by GlaxoSmithKline; Rating Change to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Downgrading to Neutral, GSK Lassos TSRO for $75/Share
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Industry: Medical - Drugs
GSK Proposes Acquisition of TESARO for $75 Per Share Cash
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
SITC Presentations Showcase TSRO?s I/O Potential and Upcoming Data
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Program Updates Presented at Investor Meeting; Interim Clinical Insights at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Q3 Financials; Zejula Growth and Burn Rate Improves, but Financing Risk Lingers
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
TESARO 3Q18 Results; Promising Zejula Sales and Pipeline Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
TESARO Announces Zejula Development Milestones; To Receive $18M From Janssen
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D